S12 Ep23: Inavolisib Expands the PIK3CA-Mutated Metastatic HR+ Breast Cancer Treatment Paradigm: With Virginia Kaklamani, MD, DSc

OncLive® On Air - En podkast av OncLive® On Air

Prøv Podimo gratis i hele 60! dager!

Prøv Podimo gratis i hele 60! dager!

I Podimo finner du eksklusive podkaster og bestselgende lydbøker tilpasset dine ører

 Reklame
Podcast artwork

Dr Kaklamani discusses the mechanism of action of inavolisib, the importance of the addition of this agent to the HR-positive metastatic breast cancer treatment paradigm, and considerations for early biomarker testing in patients with breast cancer.

Visit the podcast's native language site